Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • uPAR-targeted radiopharmaceuticals
    • MNPR-101
      • Overview
      • Development Strategy
      • SNMMI Poster June 2024
      • EANM Presentation October 2024
    • Collaborations
      • Overview
      • Current Collaborations
    • Publications
      • MNPR-101
    • ALXN1840
      • EASL Poster May 2025
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Careers Careers
  • Contact Us Contact Us
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar to Present at the 35th Annual Roth Conference

Mar 7, 2023

Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials

Feb 27, 2023

Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin

Feb 14, 2023

Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT

Jan 26, 2023

Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2

Jan 18, 2023

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

Dec 12, 2022

Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial

Nov 16, 2022

Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments

Nov 10, 2022

Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202

Oct 27, 2022

Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting

Oct 19, 2022
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...12
    • About
    • Pipeline
    • Investors
    • Our Team
    • Careers
    • Contact Us
    • Pipeline
    • Pipeline Chart
    • uPAR-targeted radiopharmaceuticals
    • MNPR-101
    • Collaborations
    • Publications
    • ALXN1840
    • Investors
    • Overview
    • Annual Meeting
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance

    Terms and Conditions of Use

    © 2025 Monopar Therapeutics Inc. All Rights Reserved.